Log In
BCIQ
Print this Print this
 

ESK1

  Manage Alerts
Collapse Summary General Information
Company Eureka Therapeutics Inc.
DescriptionHuman IgG1 T-cell receptor mimic mAb targeting Wilms tumor 1 (WT1)
Molecular Target Wilms tumor 1 (WT1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLeukemia
Indication DetailsTreat leukemia
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today